The global in vitro toxicology testing market is projected to exceed $20.97 billion by 2031, according to a new industry analysis. The outlook points to rising demand for test methods that reduce or replace animal use, while also highlighting the growing role of artificial intelligence in improving screening, analysis and decision-making across toxicology workflows.
The report examines the market across multiple segments, including product categories, toxicity endpoints and type, technology, method, services and regional performance. That broad breakdown suggests continued interest from pharmaceutical, biotechnology, chemical and related industries that need faster and more scalable ways to assess safety during research and product development.
A major theme in the forecast is the shift toward non-animal testing approaches. In vitro methods are gaining traction as companies and regulators look for alternatives that can support efficiency, consistency and evolving ethical standards. At the same time, AI-based tools are becoming more relevant as laboratories seek to interpret complex data sets and streamline testing strategies.
The competitive landscape highlighted in the analysis includes Thermo Fisher Scientific, Agilent Technologies, Merck, Eurofins Scientific and Charles River Labs, among other established participants. Their presence underlines how the market is being shaped by a mix of instrument providers, testing specialists and life sciences companies expanding capabilities in modern toxicology assessment.
